Two sham-controlled trials seemingly showed a placebo-resistant benefit to ablation for AF, but the larger SHAM-PVI-AF trial calls those results into question.
Market Samachar is a news aggregator. This article was originally published by Medscape. Tap the button above to read the full story on their site.